Humboldt Fund
VC Fund
New York, United States
Humboldt Fund is an investment firm that seeks to invests in bio revolution companies.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 21%
Last updated:
For AI agents: llms.txt
Industries Humboldt Fund invests in
Stages Humboldt Fund invests in
Countries Humboldt Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $1.5M–$16M
- Series A
- $23M–$80M
- Series B
- $34M–$175M
Investment Focus
Industry
- Biotechnology 14 (50%)
- Food and Beverage 7 (25%)
- Medical 4 (14%)
- Health Care 4 (14%)
- Therapeutics 4 (14%)
Stage
- Seed 8 (29%)
- Series A 7 (25%)
- Series B 4 (14%)
- Venture - Series Unknown 4 (14%)
- Pre-Seed 1 (4%)
Country
- United States 16 (57%)
- Chile 1 (4%)
- China 1 (4%)
- Switzerland 1 (4%)
- The Netherlands 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Benjamin Quiroga
Founder & Co-Founder
|
Founder & Co-Founder | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Spiral Therapeutics
|
Spiral Therapeutics is a clinical stage pharmaceutical company delivering novel therapies for hearing loss. Through the use proprietary therapeutics and drug delivery technologies, Spiral is building a pipeline of advanced therapies in a field with large unmet needs and no approved therapies. Spiral’s lead candidate, LPT99, reached the clinic inDecember 2018. Spiral was launched in early 2016 and is headquartered in Brisbane, CA. | $8.3M / Venture - Series Unknown / Jan 09, 2023 | |
Deciduous Therapeutics
|
Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune-modulatory therapies that clear senescent cells and promote a healthy lifespan. Deciduous is led by Anil Bhushan, a professor at UCSF, and Robin Mansukhani, a five-time biotech founder. | $10M / Seed / Dec 31, 2022 | |
Endpoint Health
|
Endpoint Health is a precision immunology company that is breaking the efficacy barrier of traditional pharma's “one-size-fits-all” drug development strategy by developing precision therapies with outsized efficacy potential in autoimmune and inflammatory conditions. They’re accomplishing this by leveraging OMNAI, their proprietary AI-poweredpatient discovery platform, to identify and match high-potential therapies to the patients most likely to respond. | $52M / Series A / Jun 02, 2022 | |
Ansa Biotechnologies
|
Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerateinnovation in biological research and engineering. | $68M / Series A / Apr 11, 2022 | |
Affini-T Therapeutics
|
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-celltherapies designed to eradicate tumors. | $175M / Venture - Series Unknown / Mar 22, 2022 | |
Finless Foods
|
Plant-based and cell-cultured seafood that changes how the world eats… and supports healthy oceans.OUR MISSION IS SIMPLE – we want to create a future where the ocean thrives. We work toward this every day by creating delicious, alternative seafood products that help you satisfy your cravings from the sea without bait or a hook. We are usingground-breaking (or rather ocean-breaking) plant and cell culture technology to revolutionize the way the world sources delicious food. Good for us. Good for the ocean. | $34M / Series B / Mar 07, 2022 | |
HAYA Therapeutics
|
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $5M / Seed / Feb 09, 2022 | |
Metagenomi
|
Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems. | $175M / Series B / Jan 25, 2022 | |
Cellino
|
Cellino is building an ultra-scalable biomanufacturing technology stack for personalized cell, tissue, and organ replacement therapies. Cellino’s vision is transform medicine to enhance healthspan for billions across generations. | $80M / Series A / Jan 25, 2022 | |
|
Ansa Biotechnologies
|
Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerateinnovation in biological research and engineering. | $5M / Oct 15, 2021 | |
| See all 28 investments → | |||
Co-Investors
Horizons Ventures
4 deals together
Leaps by Bayer
4 deals together
Mubadala Capital Ventures
4 deals together
RA Capital Management
4 deals together
SOSV
4 deals together
Agent Capital
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Humboldt Fund invest in?
Humboldt Fund invests primarily in Biotechnology, Food and Beverage and Medical startups, most often at Seed and Series A stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Humboldt Fund's check size?
Humboldt Fund typically joins rounds of $1.5M–$16M at Seed, $23M–$80M at Series A and $34M–$175M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Humboldt Fund participates in.
How do I contact Humboldt Fund?
Public channels for Humboldt Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Humboldt Fund?
The team at Humboldt Fund includes Benjamin Quiroga (Founder & Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
